Business intelligence reports for the lab diagnostics industry
Subscribe for Exclusive Access.
Subscriptions & Reports
Interested in multiple copies or more than one of our G2 reports?
Call Sokha at 855-528-6903 or email spearson@g2intelligence.com to discuss pricing.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
Coverage for Electron Microscopy Left to MACs
By Christopher P. Young, Editor, G2 Compliance Advisor The Centers for Medicare and Medicaid Services (CMS) has removed the national coverage determination (NCD) for electron microscopy (EM) from the Medicare National Coverage Determinations Internet only manual...
FDA, AACR and ASCO Seeking to Harmonize Companion Diagnostics for Cancer Treatments
By Kelly A. Briganti, Editorial Director, G2 Intelligence Concerned that cancer patients may not receive "optimal care" when there are "multiple targeted therapy-companion diagnostic pairs," the U.S. Food and Drug Administration (FDA), American Association for...
Quest Strikes Deal With Personalis on Pediatric Exome Testing
By Ron Shinkman, Editor, Laboratory Industry Report Quest Diagnostics has teamed with the California-based testing firm Personalis to provide a whole exome sequencing product to detect rare genetic disorders among pediatric patients. The product, known as Neurome,...
Online Marketing of Personalized Oncology Services May Be Misleading
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Online marketing of personalized cancer tests and services frequently overemphasize their reported benefits, neglect to disclose their limitations, and promote genetic tests that do not have...
HHS Declares Enterovirus D68 Significant Potential for Public Health Emergency
By Kelly A. Briganti, JD, Editorial Director, G2 Intelligence The U.S. Department of Health and Human Services Secretary issued a notice declaring the enterovirus D68 (EV-D68) poses a “significant potential for a public health emergency that has a significant...
Oncotype DX Use Consistent With Guidelines, Study Finds
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Oncotype DX assay (Genomic Health; Redwood City, Calif.), to assess a patient's risk of recurrence, was adopted quickly in clinical practice after Medicare's positive coverage decision,...
Castle Biosciences Study Reaffirms Efficacy of Predictive Melanoma Test
By Ron Shinkman, Editor, Laboratory Industry Report A new clinical study conducted in conjunction with the Texas-based Castle Biosciences, Inc. suggests that its molecular assay for melanoma patients can assist in determining whether their particular cancer will...
Annual Physician Fee Schedule Game Begins
By Christopher P. Young, Editor, G2 Compliance Advisor The Medicare physician fee schedule (MPFS) will be adjusted to reflect a 21.2 percent negative update effective April 1 unless Congress acts to override or delay the cut as has been the case in previous years....
AMP Releases Tools to Calculate Cost, Demonstrate Value of Genome Sequencing
By Stephanie Murg, Managing Director, G2 Intelligence No discussion of next-generation sequencing (NGS) is complete without a reference to the swiftly plummeting cost of the technology, and yet little effort has made to put a dollar figure on the value of this type...